Bridgebio Pharma, Inc. revenue
Bridgebio Pharma, Inc.'s revenue was $502m in fiscal 2025, up 126.3% on the year before. Since fiscal 2019 ($40.6m) it has grown at a compound 52.1% a year. Over the last twelve months it was $946m.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 8 | 70 | 78 | 9 | 222 | 502 | 946 |
| Growth on the year before | — | −79.7% | +745.1% | +11.4% | −88.0% | +>999% | +126.3% | — |
| Gross profit | — | — | 67 | 74 | 7 | 218 | 481 | 892 |
| Gross margin | — | — | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% | 94.3% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $362M | 72.2% | ▲ 12464.8% |
| Licenses and services | $128M | 25.6% | ▼ 41.4% |
| Royalty | $11.4M | 2.3% | ▲ 6637.3% |
From Bridgebio Pharma, Inc.'s 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Bridgebio Pharma, Inc. | $946m | 167.3% | 364.6% |
| Kiniksa Pharmaceuticals International, plc | $946m | 58.2% | 56.1% |
| Biocryst Pharmaceuticals Inc | $941m | 68.7% | 45.3% |
| Ionis Pharmaceuticals Inc | $874m | -7.4% | 11.5% |
| Legend Biotech Corp | $1.03bn | 64.0% | — |
| Ascendis Pharma A/s | $814m | 106.9% | — |
Compare with peers
- Kiniksa Pharmaceuticals International, plc revenue
- Biocryst Pharmaceuticals Inc revenue
- Ionis Pharmaceuticals Inc revenue
- Legend Biotech Corp revenue
- Ascendis Pharma A/s revenue
Head to head: BBIO vs KNSABBIO vs BCRXBBIO vs IONSBBIO vs LEGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies